Pegylated liposomal doxorubicin
Showing 1 - 25 of 2,756
Platinum-resistant Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- pegylated liposomal doxorubicin
- (no location specified)
Aug 2, 2023
Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)
Not yet recruiting
- Kaposi Sarcoma
- HIV-1-infection
- Pegylated liposomal doxorubicin
- Paclitaxel
- (no location specified)
Jan 20, 2023
Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)
Recruiting
- Ovarian Cancer Recurrent
- IN10018
- +2 more
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Science and Peking Un
Aug 23, 2023
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)
Completed
- Breast Cancer
- Trastuzumab and non-pegylated liposomal doxorubicin
-
Paris, France
- +3 more
Feb 8, 2022
Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)
Recruiting
- Breast Cancer
- sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
May 22, 2022
Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)
Completed
- Breast Cancer
- Pegylated liposomal doxorubicin
-
Tucson, Arizona
- +1 more
Jan 9, 2023
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +
Not yet recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- Pegylated Liposomal Doxorubicin + SL-172154
- Mirvetuximab + SL-172154
- (no location specified)
Jul 29, 2022
Advanced Breast Cancer Trial in Shanghai (Pegylated Liposomal Doxorubicin)
Recruiting
- Advanced Breast Cancer
- Pegylated Liposomal Doxorubicin
-
Shanghai, ChinaFudan University Cancer Hospital
Apr 19, 2022
Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))
Recruiting
- Breast Cancer
- pegylated liposomal doxorubicin (PLD)
- +5 more
-
Guandong, Guangdong, ChinaSunyat-sen Memorial Hospital
Feb 17, 2022
Ovarian Cancer Trial in Indianapolis, Madison (Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120)
Terminated
- Ovarian Cancer
- Doxil (Pegylated Liposomal Doxorubicin)
- BIBF 1120
-
Indianapolis, Indiana
- +1 more
Feb 14, 2022
Relapsed Sarcomas Trial in Cleveland (Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil))
Not yet recruiting
- Relapsed Sarcomas
- Disulfiram
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Apr 18, 2022
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Pegylated Liposomal Doxorubicin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 15, 2023
Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in Santa Monica, Pittsburgh, Houston (TTI-622, Pegylated Liposomal
Recruiting
- Ovarian Cancer
- +5 more
- TTI-622
- Pegylated Liposomal Doxorubicin
-
Santa Monica, California
- +4 more
Jul 26, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)
Completed
- Advanced Ovarian Cancer
- Olaparib
- Pegylated Liposomal Doxorubicin
-
Sabadell, Barcelona, Spain
- +7 more
Jan 25, 2023
Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 19, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Ovarian Cancer Trial in Villejuif (Pembrolizumab, Bevacizumab, pegylated liposomal doxorubicin (PLD))
Active, not recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Jul 21, 2021
Efficacy and Safety Trial in Zhejiang (pegylated liposomal doxorubicin, paclitaxel, Carboplatin)
Active, not recruiting
- Efficacy and Safety
- pegylated liposomal doxorubicin
- +2 more
-
Zhejiang, Hangzhou, ChinaWomen's Hospital School Of Medicine Zhejiang University
Jul 14, 2022
Breast Cancer Trial in Taiwan (Epirubicin+Cyclophosphamide, liposomal-doxorubicin+Cyclophosphamide)
Active, not recruiting
- Breast Cancer
-
Changhua, Taiwan
- +8 more
Nov 22, 2021
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)
Active, not recruiting
- Invasive Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022